MRNA Vaccines

Srishti Therapeutics

Overview

Srishti Therapeutics is developing mRNA vaccines targeting vector-borne diseases using hybrid antigen design. Supported by philanthropic grants, the project is advancing toward IND readiness and exploring new financial mechanisms to scale impact across underserved regions.

Remix this Asset

Focused on neglected diseases

01

Targets dengue, chikungunya, and other high-burden vector-borne illnesses lacking vaccine solutions.

Hybrid antigen strategy

02

Combines traditional epitope mapping with novel mRNA payloads for broadened immune protection.

IND pipeline in motion

03

Backed by early philanthropic capital, now structuring toward regulatory and commercial readiness.

Modular bioscience, at your fingertips